Cargando…
驱动基因阳性非小细胞肺癌免疫治疗进展
Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after t...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976200/ https://www.ncbi.nlm.nih.gov/pubmed/35340163 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.06 |
_version_ | 1784680513407025152 |
---|---|
collection | PubMed |
description | Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation. |
format | Online Article Text |
id | pubmed-8976200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-89762002022-04-19 驱动基因阳性非小细胞肺癌免疫治疗进展 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation. 中国肺癌杂志编辑部 2022-03-20 /pmc/articles/PMC8976200/ /pubmed/35340163 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.06 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title_full | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title_fullStr | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title_full_unstemmed | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title_short | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
title_sort | 驱动基因阳性非小细胞肺癌免疫治疗进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976200/ https://www.ncbi.nlm.nih.gov/pubmed/35340163 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.06 |
work_keys_str_mv | AT qūdòngjīyīnyángxìngfēixiǎoxìbāofèiáimiǎnyìzhìliáojìnzhǎn AT qūdòngjīyīnyángxìngfēixiǎoxìbāofèiáimiǎnyìzhìliáojìnzhǎn AT qūdòngjīyīnyángxìngfēixiǎoxìbāofèiáimiǎnyìzhìliáojìnzhǎn AT qūdòngjīyīnyángxìngfēixiǎoxìbāofèiáimiǎnyìzhìliáojìnzhǎn AT qūdòngjīyīnyángxìngfēixiǎoxìbāofèiáimiǎnyìzhìliáojìnzhǎn |